Skip to main content
Genome&Company logo

Genome&Company — Investor Relations & Filings

Ticker · 314130 ISIN · KR7314130006 KO Manufacturing
Open in API
Filings indexed 427 across all filing types
Latest filing 2025-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 314130

About Genome&Company

http://genomecom.co.kr/

Genome&Company is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapeutics. The company's research and development pipeline is centered on two primary platforms: microbiome-based pharmaceuticals and novel immune checkpoint inhibitors for immuno-oncology. Its drug candidates are derived from its proprietary microbiome platform and are aimed at treating a range of diseases, with a significant focus on cancer. In addition to its pharmaceutical programs, the company develops and markets consumer healthcare products, including dietary supplements and cosmeceuticals, leveraging its expertise in microbes and probiotics.

Recent filings

Filing Released Lang Actions
분기보고서 (2025.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company 'Genome&Company' covering the period from January 1, 2025, to March 31, 2025. It contains detailed corporate information, business descriptions, capital changes, and financial disclosures, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-05-15 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed with the Financial Supervisory Service (FSS) in South Korea. It details changes in share ownership by a major shareholder (Park Hansoo) and related parties in Genome & Company. This type of filing is a mandatory regulatory disclosure for significant changes in shareholding (crossing thresholds), which falls under the 'Major Shareholding Notification' category.
2025-05-09 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. It details the change in share ownership by a director (Park Hansoo) of Genome & Company. This type of filing is specifically categorized as 'Director's Dealing' (DIRS) as it reports personal share transactions by company executives.
2025-05-09 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details changes in share ownership by a major shareholder (Pae Jisoo) and their special related parties in the company 'Genome & Company'. This document type is specifically used to notify the market and regulators of significant changes in shareholding levels, which falls under the 'Major Shareholding Notification' category.
2025-05-09 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities (Financial Supervisory Service/Korea Exchange). It details a change in share ownership by an executive (CEO Bae Jisoo) due to a gift of shares. This type of filing is specifically categorized as a 'Director's Dealing' (DIRS) report, as it tracks insider transactions and changes in holdings by company directors and major shareholders.
2025-05-09 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service (FSS) and Korea Exchange. It details specific share transactions (an increase in holdings due to a gift from the CEO) by an executive (Kim Sangkyun) of Genome & Company. This type of filing is a standard regulatory disclosure for insider trading or changes in executive shareholdings, which corresponds to the 'Director's Dealing' category.
2025-05-09 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.